# Resveratrol Cardiovascular Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/resveratrol-cardiovascular-randomized-trial-evidence-review
Category: evidence-review
Summary: Resveratrol Cardiovascular Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass
Last reviewed: 2026-07-06
Reviewed by: Migaku Evidence Review
# Resveratrol Cardiovascular Randomized Trial: What the Evidence Says

## Quick Answer

Resveratrol Cardiovascular Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 randomized trial.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review | systematic review | 1 | 2026-05-26 | 10.3390/molecules31111837 |
| The effects of resveratrol on endothelial progenitor cells and apoptosis biomarkers in postmenopausal women with chronic coronary heart disease: a randomized controlled trial | randomized trial | 2 | 2026-05-14 | 10.3389/fnut.2026.1814668 |

## What The Sources Report

- Obesity, defined as excessive accumulation of adipose tissue, is strongly associated with metabolic complications, including hypertension, dyslipidemia, and type 2 diabetes. [Gazda Patrycja (2026); evidence level 1]
- Chronic low-grade inflammation associated with obesity contributes to metabolic dysfunction through the increased production of pro-inflammatory cytokines and adipocytokines. [Gazda Patrycja (2026); evidence level 1]
- After the decline in estrogen levels in menopause, the higher CVD incidence and risk found in this population were associated with structural and functional alterations in cardiovascular system, suggesting a key role of estrogens. [Gonçalinho Gustavo Henrique Ferreira (2026); evidence level 2]
- The main CVD associated with deaths and loss of quality of life in this group is coronary heart disease (CHD), which has atherosclerosis as its pathophysiological basis and a multifactorial etiology. [Gonçalinho Gustavo Henrique Ferreira (2026); evidence level 2]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. There is trial evidence in the current set, but population and intervention details still matter. For resveratrol cardiovascular randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Gazda Patrycja (2026). The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review. DOI: 10.3390/molecules31111837. PMCID: PMC13258050. PMID: 42280140. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13258050/
- Gonçalinho Gustavo Henrique Ferreira (2026). The effects of resveratrol on endothelial progenitor cells and apoptosis biomarkers in postmenopausal women with chronic coronary heart disease: a randomized controlled trial. DOI: 10.3389/fnut.2026.1814668. PMCID: PMC13215931. PMID: 42221785. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13215931/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.